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Pharmazentrum Frankfurt/ZAFES, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt am Main, Germany
The ubiquitous mRNA binding protein human antigen R (HuR), a member of
the embryonal lethal abnormal vision protein family has a critical impact on the
post-transcriptional control of AU-rich element bearing mRNA regulons implied in
inflammation, senescence, and carcinogenesis. HuR in addition to mRNA stability can
affect many other aspects of mRNA processing including splicing, polyadenylation,
translation, modulation of miRNA repression, and intracellular mRNA trafficking. Since
many of the identified HuR mRNA targets (“HuR mRNA regulons”) encode tumor-
related proteins, HuR is not only discussed as an useful biomarker but also as
promising therapeutic target for treatment of various human cancers. HuR which is
most abundantly localized in the nucleus is translocated to the cytoplasm which is
fundamental for most of the described HuR functions on target mRNAs. Accordingly,
an elevation in cytoplasmic HuR was found in many tumors and correlated with a high
grade of malignancy and a poor prognosis of patients. Therefore, direct interference
with the intracellular trafficking of HuR offers an attractive approach to intervene with
pathologically deregulated HuR functions. Data from several laboratories implicate
that the integrity of the cytoskeleton is critical for HuR-mediated intracellular mRNA
localization and translation. This review will particularly focus on drugs which have
proven a direct inhibitory effect on HuR translocation. Based on the results from those
studies, we will also discuss on the principle value of targeting cytoskeleton-dependent
transport of HuR by natural or synthetic inhibitors as a potential therapeutic avenue
for interfering with dysregulated post-transcriptional HuR mRNA regulons and related
tumor cell functions. In spite of that, interfering with cytoplasmic HuR transport could
highlight a so far underestimated action of microtubule inhibitors clinically used for
cancer chemotherapy.
Keywords: cytoskeleton inhibitors, HuR, RNA binding protein, mRNA stability, mRNA trafficking
INTRODUCTION
Modulation of mRNA turnover and translation reflect key paradigms of post-transcriptional gene
regulation in physiology and pathology of higher eukaryotes. Besides mutations in the genome,
tumor-related gene expression profiles frequently rely on alterations in post-transcriptional
control mechanisms. Together with the non-coding RNAs, particularly the micro RNAs which
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either affect transcript stability or the level of the encoded protein,
RNA binding proteins (RBPs) have a critical impact on various
mRNA modalities (Keene and Tenenbaum, 2002; Keene, 2007).
The ubiquitously expressed turnover and translation regulatory-
RNA binding protein (TTR-RBP) human antigen R (HuR), a
member of the embryonic lethal abnormal vision (ELAV) like
protein family is one of the best characterized RBP in this
scenario. In addition to mRNA stability and translation, HuR can
affect additional RNA features namely splicing and intracellular
transport of mRNA with the latter one being highly relevant
for spatial control of protein synthesis (for review see: Tekotte
and Davis, 2002; Martin and Ephrussi, 2009). Members of the
Hu protein family, target many short-lived mRNAs preferentially
those bearing destabilizing AU-rich elements (AREs) in their 3′or
5′untranslated regions (UTRs) which have also been summarized
as post-transcriptional “Hu-mRNA regulons” (Ma et al., 1996;
Myer et al., 1997; Pascale and Govoni, 2012). A large variety
of these mRNAs encode proteins which implement hallmarks
of cancer including proliferation, cell survival, immune evasion,
angiogenesis, and metastasis (for review see: Mazan-Mamczarz
et al., 2008; Abdelmohsen and Gorospe, 2010). Accordingly, an
upregulation of HuR was observed in many tumors (López de
Silanes et al., 2005; Abdelmohsen and Gorospe, 2010; Wang et al.,
2013). It is for this reason that, HuR is considered a promising
target of novel anticancer therapies. Nevertheless, keeping in
mind that HuR is indispensable and necessary for normal life
and development (Ghosh et al., 2009), approaches aiming at
the total knockdown of HuR expression have to be considered
with caution. Alternative strategies which would allow for only
a temporal intervention with some specific HuR activies are
therefore certainly much more desirable.
Similar to many other RBPs, HuR is a typical shuttling
protein which translocates from the nucleus to the cytoplasm and
backward (“HuR shuttling”). Pathologically, elevated cytoplasmic
HuR levels in patients correlate with an increase in tumor size,
higher invasion and poor outcome as convincingly demonstrated
in ovarian (Erkinheimo et al., 2003), breast (Heinonen et al.,
2005), and colorectal cancer, respectively (Denkert et al., 2006).
Structurally, the bidirectional transport of HuR is related to
the HuR nucleocytoplasmic shuttling sequence (HNS) residing
within the hinge region of the protein. Transport of HuR across
the nuclear envelope requires an interaction of the HNS with
components of the nucleo-cytoplasmic transport machinery,
including transportins 1 and 2 (Rebane et al., 2004), importin-1α
and the export route via the chromosome region maintenance 1
(CRM1) nuclear pore receptor also known as exportin 1 (Siddiqui
and Borden, 2012). Importantly, in most cell types the shuttling
of HuR is not a constitutive process but transiently induced by
activation of different signaling devices (Kim et al., 2008; Doller
et al., 2010). Accordingly, redistribution of HuR is a direct target
of specific post-translational modifications including methylation
(Li et al., 2002), and protein kinase dependent phosphorylation
(Abdelmohsen et al., 2007; Doller et al., 2007, 2008). Importantly,
these protein kinases, e.g., checkpoint kinase 2 (Chk2) and
enzymes of the protein kinase C family have also been implicated
in the regulation of tumor-related processes (for a review see:
Doller et al., 2008).
CYTOSKLETON DEPENDENT HUR
TRANSPORT
In addition to HuR’s nucleo-cytoplasmic transit, the specific
cytoplasmic HuR localization, e.g., to the translation apparatus,
the exosomes or the processing (P)-bodies for storage of
mRNA is an important determinant for the destiny of the
HuR-bound target mRNAs. Directed mRNA transport to a
distinct cytoplasmic destination is furthermore highly relevant
for spatial and temporal control of protein synthesis (Hovland
et al., 1996; Tekotte and Davis, 2002; Martin and Ephrussi,
2009). Previous data demonstrated that the ubiquitously
expressed HuR (Cheng et al., 2013; Doller et al., 2013) and
its neuronal relative HuD (Fujiwara et al., 2011) can utilize
either the actin- or microtubule-dependent cytoskeleton for
transport of mRNA cargo. Interestingly, the nuclear export
of HuR seems closely linked to its cytoplasmic trafficking
since pharmacological disruption of either of both cytoskeletal
transport systems prevents accumulation of HuR protein in the
cytoplasm (Cheng et al., 2013; Doller et al., 2013). Targeting
of both transport systems therefore represents a valuable
approach to intervene with post-transcriptional ELAV/Hu
mRNA regulons.
INTERFERING WITH
MICROTUBULE-DEPENDENT HUR
TRANSPORT
A growing list of chemically diverse compounds perturbing
the dynamics of microtubules have proven clinical efficacy
in the treatment of various human cancers. The main
therapeutic effect of currently used microtubule inhibitors
seems to arise from cell cycle arrest due to inhibition of
the mitotic spindle typically followed by an induction of
apoptosis due to mitotic catastrophe (Jordan et al., 1996;
Huszar et al., 2009). Microtubule destabilizing drugs as the
vinca alkaloids vinblastine and vincristine from the Madagascar
periwinkle Catharanthus roseus or, colchicine, an alkaloid derived
from the autumn crocus Colchicum autumnale prevent the
polymerization of microtubules (Huszar et al., 2009). In contrast,
microtubule stabilizers such as paclitaxel or the hemisynthetic
taxol docetaxel prevent the depolymerization of tubulin (Jordan
and Wilson, 1998). Despite of their antagonistic effects on tubulin
polymerization, all of these compounds are potent inhibitors
of mitosis (Jordan and Wilson, 1998). In addition to affecting
mitosis, microtubules are important for cell motility and for
transport of organelles, vesicles and are relevant for long-distance
transport of protein and mRNA (for review see: Holt and Bullock,
2009; Blower, 2013). The microtubule-RNA contact needed for
RNA transport is mediated by formation of a ternary complex
between the RBP, a microtubule-associated protein (MAP) and
the zipcode which in most cases resides in the 3′UTR of the
mRNA (Antic and Keene, 1998). Importantly, transport of an
mRNA does not exclusively occur via one distinct cytoskeletal
route but can switch between actin-and microtubule-directed
transport system as demonstrated for β-actin mRNA (Martin
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and Ephrussi, 2009). A prominent example for microtubule-
dependent mRNA transport is HIF-1α. Searching for novel
pharmacological inhibitors for HIF1α, the administration of
the indoline sulfonamide MPT0B098 a novel small-molecule
inhibitor of microtubule polymerization to lung adenocarcinoma
A549 cells efficiently impaired HIF1α-triggered gene expression
(Cheng et al., 2013). These sulfonamide-based compounds were
synthesized in order to overcome various modes of resistance
and to achieve an improved pharmacological profile when
compared to clinically established microtubule inhibitors (Nien
et al., 2010). Mechanistically, MPT0B098 binds directly to the
colchicine-binding moiety of tubulin. The destabilization of
HIF1α mRNA by MPT0B098 was shown to be mainly due to
inhibition of nucleo-cytoplasmic HuR shuttling (Cheng et al.,
2013). Since HIF1α itself targets a large variety of genes,
MPT0B098 interferes with the post-transcriptional expression
of many tumor-related genes involved in tumor growth, cell
metabolism, cell survival, and other functions. Furthermore,
MPT0B098 has antiangiogenic properties as it affects the growth
and density of microvessels in tumor specimens (Cheng et al.,
2013). The pharmacological benefit of MPT0B098 is furthermore
highlighted by strong antiproliferative effects even on multidrug-
resistant human cancer cells (Nien et al., 2010). Similar to
other microtubule-targeting drugs, MPT0B098 can induce cell
growth arrest by avoiding the transition of cells from G2 to the
M phase (Cheng et al., 2013). In contrast to MPT0B098, the
microtubule stabilizing taxene docetaxel was found to increase
HuR-mediated stabilization of COX-2 mRNA in the mammary
epithelial cell line 184B5/HER mainly through and activation
of the p38 mitogen activated (MAP) kinase and PKC mediated
signaling mainly due to the induction of stress (Subbaramaiah
et al., 2000, 2003). Notably, the stimulatory effect on COX-
2 mRNA stability by taxanes demonstrated in this cell line is
mainly relying on an increased HuR binding to the 3′UTR
of the COX-2 mRNA. Since HuR phosphorylation by p38
MAPK and PKC can activate HuR-dependent stabilization on
target mRNA (Lafarga et al., 2009; Doller et al., 2010) the
net effect on HuR mRNA regulons by taxanes may critically
depend on the extent of drug-induced activation of these stress
kinases in a given cell type. In another study, microtubule
perturbation by taxol or vinblastine inhibit HIF1α expression
through the polysomal release of HIF1α mRNA although the
authors did not formally demonstrate a direct correlation of the
disrupted HIF1α mRNA transport with HuR (Carbonaro et al.,
2011). Instead, a functional role of the microtubule-dependent
cytoskeleton in the control of protein translation by HuR was
highlighted by a report from Antic and Keene (1998). These
authors demonstrated a critical role of microtubule-associated
ELAV proteins in targeting mRNP particles from RNPs to the
translation apparatus. Mechanistically, the interaction between
ELAV proteins and microtubules is thought to be indirect and
mediated, e.g., by MAPs. In case of HuD, the light chain of
MAP1B (LC1) is linking the RBP-bound mRNA to microtubules,
a process which is critical for the long-distance transport of
ARE-containing mRNAs in neurons (Fujiwara et al., 2011).
Given the plethora of tumor related genes targeted by HuR,
it is plausible that in addition to interfering with tumor cell
mitosis, an inhibition of post-transcriptional HuR regulons may
essentially contribute to the potent antitumorigenic activity of
clinically established microtubule inhibitors. In addition to the
clinically established microtubule targeting drugs, microtubule-
associated motor proteins, namely the kinesins have gained
increased attention as novel targets for cytoskeleton-interfering
therapies (Huszar et al., 2009). To date, more than 14 different
kinesin protein families with an overall of 600 kinesins have
been identified. Many of them are not only involved in
mitosis regulation, but are highly relevant for microtubule
dependent intracellular transport as well. Currently, there is
pharmacological effort to test synthetic kinesin inhibitors in
phase I and phase II trials in order to overcome side effects and
drug resistance often observed with conventional microtubule
inhibitors. It would be interesting to investigate some of the most
promising kinesin inhibitors for their potential suppressive effect
on HuR shuttling and related RNA trafficking.
INTERFERING WITH
ACTOMYOSIN-DEPENDENT
TRANSPORT
The actin-based cytoskeleton is involved in different cellular
processes including cell shapening, cell motility, cell adherence,
endocytosis and exocytosis, and intracellular transport of cargo.
Therefore, it represents another attractive target for cancer
chemotherapy (Jordan and Wilson, 1998). However, due to the
lack of specificity for different types of actin, the use of most
actin-targeting inhibitors tested so far have proven detrimental
“off target” effects (Fenteany and Zhu, 2003). Nevertheless,
compounds which preferentially act on cytoskeletal actin while
having only week effects on cardiac, muscle, or smooth muscle
actin represent attractive candidates for novel cancer therapy.
Inhibitors of Actin-Polymerization
Promising candidate compounds which may at least partially
fulfill the above mentioned criteria are the marine derived
macrolides latrunculin A and B isolated from the Red Sea sponge
Negombata magnifica. Latrunculins reversibly bind to actin
monomers by forming a stoichiometrically fixed 1:1 complex
with G actin, thereby avoiding the assembly of actin monomers
into filaments allosterically (Morton et al., 2000; Allingham et al.,
2006). Due to a more definable mode of action, latrunculins
are considered as more potent than the fungal cytochalasins
which mainly act through binding to F-actin polymer thus
preventing a further polymerization of actin monomers
(Fenteany and Zhu, 2003). Pharmacologically, latrunculins by
disrupting microfilament-mediated processes interfere with
several tumor-related cell functions including angiogenesis,
metastasis, cytokinesis, and proliferation. A strong anticancer
effect in vivo has been demonstrated in a mouse xenograft
model of human gastric cancer (Konishi et al., 2009). We
previously have demonstrated a direct and critical involvement
of actin-dependent HuR transport in the stabilization of some
prototypical HuR mRNA targets in renal mesangial cells
implicated in hypertension-induced fibrosis and inflammation
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FIGURE 1 | Schematic summary of pharmacological stratagies aiming at the inhibition of post-transcriptional HuR mRNA regulons by interfering
with cytoskeleton-dependent intracellular HuR-mRNA transport. The cytoplasmic transport of HuR bound mRNA cargo occurs in form of a remodeled
ribonucleoprotein (RNP) particle by a mechanism which requires either the actin-myosin based (Right) or microtubule dependent (Left) cytoskeleton. The
hypothetical connection between cytoskeletal elements (microfilaments, microtubules) and the nuclear pore complex is indicated by a question mark. HuR bound
target mRNAs are further directed to their final destination (turnover or translation) via a motor-driven transport along actin filaments (Right), or along microtubuli
(Left). Pharmacological inhibitors of the actomyosin dependent cytoskeleton (Right) including actin inhibitors and myosin II inhibitors or drugs which affect the
(de)polymerization of microtubules (Left) with a potential effect on cytoplasmic HuR transport are listed. Those cytoskeleton Inhibitors which have proven a direct
effect on cytoplasmic HuR abundance in the literature are highlighted in red color.
(Doller et al., 2009, 2013). Importantly, the suppressive effects
on cytoplasmic HuR accumulation and post-transcriptional
HuR-mRNA regulons by latrunculin could be confirmed
in hepatocellular carcinoma cells (Doller et al., 2015). The
inhibition of cytoplasmic HuR by latrunculin presumably relies
on the abrogated nuclear HuR export to the cytoplasm and
implicates an actin-mediated communication between both
compartments (Figure 1) which is also relevant for other RBPs
(for a review see: Farina and Singer, 2002). In addition to the
impaired HuR shuttling, latrunculin markedly decreased the
stability of prototypical HuR targets including COX-2, cyclin A
and cyclin D mRNAs concomitant with a significant reduction in
the levels of corresponding proteins. In summary, we conclude
that depending on which cell-type is analyzed, HuR utilizes
either microfilament – or microtubule guided transport for
targeting mRNA cargo to the translation apparatus. This raises
the question of how binding to a specific mRNA may principally
affect HuR’s association with preferentially one particular
cytoskeletal tracking system. Data from our laboratory suggest
that protein kinase-dependent phosphorylation of HuR confers a
preferential HuR binding to only a subset of mRNA targets with a
common zipcode in their respective 3′UTRs (Schulz et al., 2013).
Similarly, these post-translational modifications may lead to a
recruitment of HuR to a distinct motor (Figure 1). In addition
to the latrunculins, a large arsenal of other actin inhibitors from
marine organisms offers a large variety of bioactive compounds
advantageous for novel anticancer approaches (Fenteany and
Zhu, 2003). Those include the spongal cyclodepsipeptide
jasplakinolide and the macrolides swinholide A, mycalodie
B, and misakinolide A (Figure 1) which are comprehensively
reviewed elsewhere (Fenteany and Zhu, 2003). Comparison of
the inhibitory capacity of these actin inhibitors on intracellular
HuR transport is an important issue which is currently addressed
in our laboratory.
Inhibitors of Non-muscle Myosin II
The myosin family of motor proteins represents an other
attractive target for intervention with actomyosin-dependent cell
motility and intracellular transport of cargo mRNA. Myosins
have attracted significant attention and have come into the
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focus of pharmacological investigations for identification of
putative targets of small molecule inhibitors. Members of the
myosin superfamily are ATP-hydrolyzing motors mediating
the contractility of actin filaments in muscle and non-muscle
cells (for a review see: Sellers, 2000). Although the specific
roles of non-muscle myosins is not fully understood they
presumably play an important role in myosin-based cell motility
(Fenteany and Zhu, 2003; Pertuy et al., 2014). In addition,
myosin IIA (MyoIIA) is highly relevant for cell adhesion and
migration (for a review see: Vicente-Manzanares et al., 2009).
Since MyoIIA is also implicated in invasiveness of tumors
it became a potential target of novel anti-cancer therapeutics
(Duxbury et al., 2004). The majority of currently designed
myosin inhibitors are non-competitive inhibitors of myosin
ATPase activity which bind to myosin at an allosteric site
outside of the ATPase binding pocket (Bond et al., 2013).
Among those, the phenyl-pyrrolidinone derivative blebbistatin
represents a highly selective inhibitor of non-muscle myosin II
ATPase activity with almost no effects on the ATPase activity
of other myosin motors (Allingham et al., 2005; Bond et al.,
2013). In addition to a strong selectivity toward non-muscle
myosin II, another important prerequisite for its principal
use in vivo is its high cell permeability. Pharmacologically,
blebbistatin by inducing an actomyosin complex disassembly
impedes inflammatory infiltration which is an important
feature of, e.g., progressive renal diseases (Si et al., 2010).
Accordingly, blebbistatin can impair the invasion of pancreatic
adenocarcinoma cells by interfering with the cell adhesion to
the extracellular matrix (Duxbury et al., 2004). In line with
these findings, we could previously demonstrate that in HepG2
cells, blebbistatin potently interferes with several HuR controlled
cell functions including migration, invasion and the increased
synthesis of prostaglandin E2 (Doller et al., 2015). Previously,
we could identify the heavy chain 9 of non-muscle myosin
IIA (MYH9) as a direct binding partner of HuR (Doller et al.,
2013). The functional importance of MYH9 in the nucleo-
cytoplasmic HuR shuttling and HuR related mRNA functions
was confirmed by RNAi-mediated loss of function approach
which showed the same inhibitory action on HuR activites as the
pharmacological approach with blebbistatin (Doller et al., 2013,
2015). Similar to latrunculin, blebbistatin impaired the physical
interaction of HuR with MYH9s indicating that ATPase activity
is required for the interaction of myosin with HuR (Doller et al.,
2015).
In a contrast to blebbistatin, the small myosin inhibitors
N-benzyl-p-toluene sulphonamide (BTS) and Butanedione
monoxime (BDM) have a stronger inhibitory effect on skeletal
muscle myosin II. However, the clinical use of these compounds
is limited by the high concentrations needed to achieve myosin
inhibition in vivo (Bond et al., 2013). Nevertheless, these
compounds account as important lead compounds for the
development of novel drugs for the treatment of diseases based on
the overactivity or dysfunction of skeletal muscle myosin (Bond
et al., 2013). Similar as with MPTOB098 and latrunculins, a
more detailed pharmacological information including data about
animal safety, pharmacokinetics and drug efficacy is also needed
for these inhibitors for a better assessment of their potential
benefit in the clinic.
CONCLUSION
The list of genes regulated by the multifunctional RBP HuR
is steadily growing and accordingly, its critical impact in
carcinogenesis was validated for almost every type of human
tumor. Therefore, HuR is considered a promising therapeutic
target for treatment of human malignant diseases. Since the
constitutively increased transport to the cytoplasm constitutes a
major principle of post-transcriptional mRNA regulons by HuR,
interfering with its subcellular redistribution reflects a valuable
approach for targeting tumorrelevant HuR-mRNA regulons.
Although cytoskeleton-dependent transport of Hu proteins was
documented only by a couple of publications, our knowledge
from directed mRNA transport implicates a stimulus- and cargo-
specific transport of both Hu proteins along different cytoskeletal
tracking systems critical for most of their cytoplasmic functions.
In addition, current pharmacological antitumor concepts aiming
at the inhibition of cytoskeletal dynamics should be reconsidered
since some of the beneficial antitumor activities of these drugs
may derive from inhibition of HuR. Besides the well-established
microtubule inhibitors, the actomyosin dependent cytoskeleton
represents another valuable target for anti-HuR strategies. The
question whether HuR trafficking in tumor cells may generally
depend on both types of transport systems, or is rather cell-type
specific is an intriguing issue which warrants future investigation.
Together with the inexhaustible source of natural actin inhibitors
a large number of synthetic inhibitors of myosin and kinesin
motors is principally available for targeting post-transcriptional
mRNA regulons by HuR and related RBPs.
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